Total Payments
$3,012
2024 Payments
$790.36
Companies
38
Transactions
144
Medicare Patients
2,137
Medicare Billing
$353,729
Payment Breakdown by Category
Food & Beverage$2,871 (95.3%)
Education$140.95 (4.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,871 | 141 | 95.3% |
| Education | $140.95 | 3 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $265.73 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $255.37 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $232.51 | 10 | $0 (2024) |
| Daiichi Sankyo Inc. | $229.55 | 9 | $0 (2024) |
| PFIZER INC. | $161.08 | 11 | $0 (2024) |
| Genentech USA, Inc. | $155.93 | 6 | $0 (2024) |
| Lilly USA, LLC | $150.45 | 4 | $0 (2021) |
| Celgene Corporation | $140.32 | 8 | $0 (2024) |
| GENZYME CORPORATION | $137.85 | 5 | $0 (2023) |
| Incyte Corporation | $131.48 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $790.36 | 40 | Genentech USA, Inc. ($142.05) |
| 2023 | $857.26 | 37 | Janssen Biotech, Inc. ($156.39) |
| 2022 | $271.48 | 15 | EISAI INC. ($41.83) |
| 2021 | $544.89 | 22 | Lilly USA, LLC ($116.56) |
| 2020 | $149.76 | 11 | E.R. Squibb & Sons, L.L.C. ($28.47) |
| 2019 | $398.10 | 19 | Merck Sharp & Dohme Corporation ($139.21) |
All Payment Transactions
144 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Genentech USA, Inc. | Itovebi (Biological), Kadcyla, Perjeta | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.14 | General |
| Category: Hematology | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Oncology | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $22.72 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.89 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Oncology | ||||||
| 07/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: BioOncology | ||||||
| 07/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.73 | General |
| Category: Hematology | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Oncology | ||||||
| 06/27/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.57 | General |
| Category: Oncology | ||||||
| 06/13/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Genentech USA, Inc. | Polivy (Biological), Columvi | Food and Beverage | In-kind items and services | $69.33 | General |
| Category: BioOncology | ||||||
| 06/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: BioOncology | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 476 | 828 | $185,847 | $75,879 |
| 2022 | 6 | 467 | 784 | $200,775 | $69,840 |
| 2021 | 6 | 640 | 978 | $240,130 | $95,940 |
| 2020 | 6 | 554 | 1,251 | $294,482 | $112,070 |
Total Patients
2,137
Total Services
3,841
Medicare Billing
$353,729
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 113 | 277 | $58,218 | $29,329 | 50.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 167 | 326 | $61,760 | $21,918 | 35.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 96 | 96 | $31,675 | $12,354 | 39.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 45 | $17,460 | $5,986 | 34.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 38 | $7,600 | $3,468 | 45.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 22 | 22 | $5,922 | $1,833 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 24 | $3,213 | $990.40 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 179 | 357 | $72,471 | $23,679 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 106 | 219 | $60,006 | $23,538 | 39.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 102 | 102 | $39,882 | $11,952 | 30.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 39 | 47 | $18,236 | $7,104 | 39.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 32 | $6,400 | $2,513 | 39.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 26 | 27 | $3,780 | $1,054 | 27.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 167 | 255 | $51,765 | $19,435 | 37.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 71 | 149 | $40,826 | $18,960 | 46.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 148 | 231 | $46,893 | $18,498 | 39.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 130 | $35,620 | $14,751 | 41.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 55 | 55 | $21,505 | $7,723 | 35.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 43 | 43 | $16,813 | $6,584 | 39.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 29 | 36 | $13,968 | $5,247 | 37.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 28 | $5,600 | $2,224 | 39.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 33 | 35 | $4,900 | $1,776 | 36.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 16 | $2,240 | $741.33 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 292 | 852 | $172,602 | $65,012 | 37.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 112 | 241 | $65,992 | $25,930 | 39.3% |
About Dr. Thomas Guerrero-Garcia, M.D
Dr. Thomas Guerrero-Garcia, M.D is a Hematology & Oncology healthcare provider based in The Woodlands, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2012. The National Provider Identifier (NPI) number assigned to this provider is 1689939993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Guerrero-Garcia, M.D has received a total of $3,012 in payments from pharmaceutical and medical device companies, with $790.36 received in 2024. These payments were reported across 144 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($2,871).
As a Medicare-enrolled provider, Guerrero-Garcia has provided services to 2,137 Medicare beneficiaries, totaling 3,841 services with total Medicare billing of $353,729. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location The Woodlands, TX
- Active Since 07/12/2012
- Last Updated 01/19/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1689939993
Products in Payments
- KEYTRUDA (Biological) $205.17
- Enhertu (Drug) $134.05
- VERZENIO (Drug) $116.56
- KRAZATI (Drug) $111.13
- DARZALEX (Biological) $99.81
- LIBTAYO (Biological) $98.63
- INJECTAFER (Drug) $95.50
- VENCLEXTA (Drug) $93.02
- SARCLISA (Biological) $91.05
- ERLEADA (Drug) $85.34
- OPDIVO (Biological) $82.58
- PEMAZYRE (Drug) $80.34
- XGEVA (Biological) $74.59
- REBLOZYL (Biological) $74.58
- Lenvima (Drug) $69.44
- Polivy (Biological) $69.33
- IMBRUVICA (Drug) $68.12
- XTANDI (Drug) $59.09
- SCEMBLIX (Drug) $57.55
- PIQRAY (Drug) $56.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in The Woodlands
Dr. Mohsen Arani, Md, MD
Hematology & Oncology — Payments: $138,400
Hematology & Oncology $138,400
Dr. Elham Abbasi-Hafshejani, M.d, M.D
Hematology & Oncology — Payments: $3,430
Hematology & Oncology $3,430
Elim Kuo
Hematology & Oncology — Payments: $1,129
Hematology & Oncology $1,129
Dr. Angela Coscio, Md, MD
Hematology & Oncology — Payments: $876.31
Hematology & Oncology $876.31
Gurdeep Sethi, Md, MD
Hematology & Oncology
Hematology & Oncology